Answers are grounded in this paper and cite their sources.
Background Hypogammaglobulinemia and associated infection risk remain significant concerns with anti-CD20 therapies in the treatment of multiple sclerosis (MS). Anti-CD20 therapies provide continuous B-cell depletion potentially compromising humoral immunity. Cladribine tablets (CladT) offer immune reconstitution through transient lymphocyte depletion followed by gradual recovery. Individual studies have explored immunoglobulin changes and infection outcomes, but comprehensive evidence comparing the safety profiles of anti-CD20s and CladT regarding hypogammaglobulinemia and infection risk is limited. Objective To systematically evaluate the impact of anti-CD20 therapies (rituximab, ocrelizumab, ofatumumab) and CladT on immunoglobulin levels and infection risk in patients with MS. Methods A systematic literature review following the PRISMA guidelines was conducted across PubMed, EMBASE, Scopus, and Google Scholar (January 2008–December 2024). Inclusion criteria encompassed patients with MS receiving rituximab, ocrelizumab, ofatumumab, or CladT with quantifiable immunoglobulin data and infection outcomes. Results Data from 16,729 patients in 43 studies (53 treatment-specific study reports) were reviewed. CladT demonstrated the most favourable immunoglobulin profile with <2.0% developing hypogammaglobulinemia and a 0.52% serious infection rate. Among anti-CD20 therapies, ofatumumab had the best outcomes (2.7% hypogammaglobulinemia; 0.38% infections), followed by ocrelizumab (1.5–19.8%; 0.80%), and rituximab (0–44%; 0.36%). Conclusion CladT demonstrated relatively consistent immunoglobulin trends, while anti-CD20 agents showed greater immunoglobulin reduction. However, heterogeneity in populations, follow-up, and definitions precludes firm comparative safety conclusions. These findings are hypothesis-generating and warrant prospective head-to-head trials to confirm relative safety profiles.
No takes yet. Share an insight, caveat, or question.
Sriwastava et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: